Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{170082,
        author = {Madhuri Bhaginath Kshirsagar and Mr. Rahul S. Mohan and Dr. Kawade Rajendra M. and Ms. Mayuri Praful Lodha},
        title = {Vonoprazan vs proton pump inhibitors: A comparative review of efficacy, safety and cost effectiveness in pepetic ulcer, GERD, H. Pylori infection},
        journal = {International Journal of Innovative Research in Technology},
        year = {2024},
        volume = {11},
        number = {6},
        pages = {3376-3384},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=170082},
        abstract = {Proton pump inhibitor medication is the standard treatment for gastro-oesophageal reflux disease (GERD), one of the most common illnesses in the world. Nonetheless, about 40% of patients have complained of resistance to this treatment in one way or another. Recently, vonoprazan received approval to treat GERD.  Because VPZ was not impacted by pH variations in preclinical research, it was 1.2–2 times more effective than PPI in both in vitro and in vivo settings.  It was demonstrated that VPZ was far more economical than PPI. According to the article's findings, VPZ is more effective, safe, and economical than PPI for treating reflux diseases and eliminating H. pylori. 
Vonoprazan should therefore be used instead of traditional PPIs for these conditions. 
Vonoprazan and other potassium-competitive acid blockers (P-CABs) are a new and diverse class of medications that competitively block the potassium binding site of gastric H+/K+ ATPase, potentially getting around the drawbacks of proton-pump inhibitors. The effectiveness of vonoprazan against proton-pump inhibitors (PPIs) for treating acid-related diseases was assessed in many research; as a result, P-CABs exhibit the same indications as PPIs},
        keywords = {PPI, H2-receptor antagonists vonoprazan, gastric ulcer, P-CAB, peptic illness, potassium-competitive acid blockers, peptic ulcer, haemorrhage, Adverse effects},
        month = {November},
        }